MIP

General Information


DRACP ID  DRACP00278

Peptide Name   MIP

Sequence  PRFWEYWLRLME

Sequence Length  12

UniProt ID  Not available

PubChem CID  Not available

Origin  E3 ubiquitin-protein ligase

Type  Synthetic peptide

Classification

  

Active ACP Cancer targeted peptides Affect cell cycle



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
-- -- -- IC50 for MDM2=0.01 µM ELISA assay Not available 1
-- -- -- IC50 for MDMX-p53=0.12 µM ELISA assay Not available 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  MDM2

Affinity  Not available

Mechanism  Inhibits MDM2-p53 Interaction

Nature  Anticancer; Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00278

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C84H116N20O18S

Absent amino acids  ACDGHIKNQSTV

Common amino acids  ELRW

Mass  192240

Pl  6.53

Basic residues  2

Acidic residues  2

Hydrophobic residues  5

Net charge  0

Boman Index  -2377

Hydrophobicity  -70

Aliphatic Index  65

Half Life 
  Mammalian: >20 hour
  Yeast: >20 hour
  E.coli: ?

Extinction Coefficient cystines  12490

Absorbance 280nm  1135.45

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 21423613

Title  mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction

Doi 10.1371/journal.pone.0017898

Year  2011

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.